3,628,245 Common Stock of GlobeImmune, Inc. are subject to a Lock-Up Agreement Ending on 27-DEC-2014.
December 26, 2014
Share
3,628,245 Common Stock of GlobeImmune, Inc. are subject to a Lock-Up Agreement Ending on 27-DEC-2014. These Common Stock will be under lockup for 180 days starting from 30-JUN-2014 to 27-DEC-2014.
Details:
The executive officers, directors, each holder of voting securities have agreed that they will not offer, sell, assign, transfer, pledge, contract to sell, or otherwise dispose of or announce the intention to otherwise dispose of, or enter into any swap, hedge 3,628,245 shares of the common stock for a period of 180 days after the effectiveness of the registration statement, without obtaining the written consent of underwriter.
Additionally, of the 235,342 shares of common stock issuable upon exercise of options outstanding as of March 31, 2014 approximately 219,850 shares will be under lock-up for 180 days after the date of this prospectus.
GlobeImmune Inc. is a biopharmaceutical company. The Company is focused on developing products for the treatment of cancer and infectious diseases based on its Tarmogen platform. The Companyâs Tarmogen platform activates the immune system by stimulating a subset of white blood cells called T cells that destroy infected or malignant cells in contrast to traditional vaccines, which predominately stimulate antibody production. Tarmogens also reduce the number and function of regulatory T cells, thus further enabling the antigen-specific cellular immune response. It has over two Tarmogen product candidates in clinical evaluation for infectious disease and multiple cancer indications. The Company's oncology product candidates include GI-6301, GI-6207 and GI-4000. The Company's infectious disease product candidates include GS-4774, GI-19000, GI-2010 and GI-18000.